• Explore /
  • Poster
  • / Peak study: A phase 3, randomized, open-label multi-center clinical study of bezuclastinib (CGT9486) and sunitinib combination versus sunitinib in patients with gastrointestinal stromal tumors (GIST).

Peak study: A phase 3, randomized, open-label multi-center clinical study of bezuclastinib (CGT9486) and sunitinib combination versus sunitinib in patients with gastrointestinal stromal tumors (GIST).

Abstract Video & Slides Poster

Authors

William Tap

William D. Tap

Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY

William D. Tap , Neeta Somaiah , Yoon-Koo Kang , Albiruni Ryan Abdul Razak , Marcelo Garrido , Ingrid M.E. Desar , Antoine Italiano , Peter Reichardt , Breelyn A. Wilky , Michael C. Heinrich , Mihaela Druta , Arun S. Singh , Steven Attia , Sebastian Bauer , Cesar Serrano , Kevin Moynihan , Julia Lawrence , Andrew J. Wagner , Jonathan C. Trent

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Sarcoma

Track

Sarcoma

Sub Track

Gastrointestinal Stromal Tumors (GIST)

Clinical Trial Registration Number

NCT05208047

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr TPS11588)

DOI

10.1200/JCO.2024.42.16_suppl.TPS11588

Abstract #

TPS11588

Poster Bd #

513a

Abstract Disclosures

Similar Posters

First Author: Michael C. Heinrich

First Author: Hidekazu Hirano

First Author: Michael C. Heinrich

First Author: Suzanne George